Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, closes a €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures

by Ysios Capital

26 days ago
Ysios Capital, Kynexis, KYN5356, brain diseases, KAT-II

This capital increase will allow Kynexis to advance the development of KYN5356, an innovative quinurenine aminotransferase II (KAT-II) enzyme inhibitor, for the treatment of cognitive impairment assoc...

SpliceBio, participada por Ysios y Asabys, recibe el premio a la 'Serie A del año' en los European Lifestars awards

by Ysios Capital

1 year ago
SpliceBio, Ysios Capital

SpliceBio, compañía biotecnológica de terapia génica con sede en Barcelona basada en tecnología desarrollada en la Universidad de Princeton, ha recibido el galardón a la “Ronda de Inversión S...

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

by Ysios Capital

2 years ago
Ysios Capital, Mineralys Therapeutics

Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-H...

Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal

by Ysios Capital

2 years ago
Ysios Capital

After a very active 2021, closing an oversubscribed €216M fund, 3 NASDAQ IPOs, and Sanifit’s landmark acquisition by Vifor Pharma, Ysios Capital is now focused on managing its portfolio companies ...

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

by Ysios Capital

2 years ago
SpliceBio, UCB Ventures, Ysios Capital, New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund, Asabys Partners

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...

NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

by Ysios Capital

2 years ago
Forbion, Ysios Capital, NASH, NorthSea Therapeutics, Icosabutate

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today an...

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

by Ysios Capital

2 years ago
Vifor Pharma, Sanifit Therapeutics, kidney disease, Ysios Capital

Vifor Pharma and Sanifit Therapeutics, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the companies hav...

Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ

by Ysios Capital

2 years ago
Ysios Capital, Aura Biosciences

Ysios Capital, a leading Spanish biotechnology venture capital firm, has announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on th...

Ysios Capital achieves Certification under the Diversity VC Standard

by Ysios Capital

2 years ago
Ysios Capital, Future VC, Diversity VC, Certification

Ysios Capital is the first specialized venture capital firm in life sciences globally and the first Spanish firm to achieve the Diversity VC Standard, an assessment and certification process that sets...

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

by Ysios Capital

2 years ago
Ysios Capital, CVRx, Inc, LAVA Therapeutics

Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company CVRx Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq Glob...

Cytoki Pharma raises $45 million Series A financing

by Ysios Capital

3 years ago
Ysios Capital, +ND Capital, Seventure Partners, Lundbeckfonden Emerge, Cytoki Pharma

Cytoki Pharma ApS, a private biotech company incorporated in Copenhagen, Denmark, today announced a $45 million series A financing led by existing investor Lundbeckfonden Emerge (Denmark) together ...

Adcendo raises EUR 51 Million in Series A Financing led by Novo Holdings and Ysios Capital to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

by Ysios Capital

3 years ago
Adcendo, Gilde Healthcare, Ysios Capital, RA Capital Management, Novo Seeds

Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...